In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Aerovate Therapeutics (AVTE – Research Report). The company’s shares opened today at $11.27.
Thome covers the Healthcare sector, focusing on stocks such as Aerovate Therapeutics, Jazz Pharmaceuticals, and United Therapeutics. According to TipRanks, Thome has an average return of -11.6% and a 30.88% success rate on recommended stocks.
Aerovate Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $33.25.
See Insiders’ Hot Stocks on TipRanks >>
Based on Aerovate Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $19.03 million. In comparison, last year the company had a GAAP net loss of $11.99 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerovate Therapeutics (AVTE) Company Description:
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.
Read More on AVTE:
